Significance of HER2/neu overexpression in pure ductal carcinoma in situ: A clinicopathologic study with long-term follow-up.

被引：1
|
作者：
Al-Mansour, Zeina [1 ]
Stockl, Thomas [1 ]
Khan, Ashraf [1 ]
Horner, Richard [1 ]
Cosar, Ediz [1 ]
Hsieh, Chung-Cheng [1 ]
Kandil, Dina [1 ]
机构：
[1] Univ Massachusetts, Sch Med, Worcester, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 26期
关键词：
D O I：
10.1200/jco.2013.31.26_suppl.85
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
85
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sequential HER2-Targeted Therapy in Salivary Ductal Carcinoma With HER2/neu Overexpression and a Concomitant ERBB2 Mutation
    Almquist, Daniel
    Umakanthan, Jayadev Manikkam
    Ganti, Apar Kishor
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 5
  • [22] Comparative study of HER2/neu, CD34 AND SMA expression in benign, In situ and invasive ductal breast carcinoma
    Parada, David
    Pena, Karla B.
    VIRCHOWS ARCHIV, 2008, 452 : S21 - S21
  • [23] Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer
    Lum, Lawrence G.
    Thakur, Archana
    Al-Kadhimi, Zaid S.
    Colvin, Gerald A.
    Cummings, Francis J.
    Legere, Robert Duffy
    Dizon, Don S.
    Kouttab, Nicola
    Maizel, Abby
    Colaiace, William
    Liu, Qin
    Rathore, Ritesh
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
    Van Bockstal, M.
    Libbrecht, L.
    Floris, G.
    Lambein, K.
    Pinder, S.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2317 - 2317
  • [25] Induction of NK cell ADCC against Her2/neu expressing ALL blasts by Trastuzumab in vitro and long term clinical follow-up of Her2/neu positive ALL patients
    Haen, S. P.
    Schmiedel, B. J.
    Roth, N.
    Moehle, R.
    Faul, C.
    Schmalzing, M.
    Kanz, L.
    Vogel, W.
    Salih, H. R.
    ONKOLOGIE, 2012, 35 : 113 - 114
  • [26] Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up
    Hieken, Tina J.
    Cheregi, John
    Farolan, Miguel
    Kim, Joan
    Velasco, Jose M.
    AMERICAN JOURNAL OF SURGERY, 2007, 194 (04): : 504 - 506
  • [27] The Significance of HER-2/neu Receptor Positivity and Immunophenotype in Ductal Carcinoma In Situ with Early Invasive Disease
    Harada, Shuko
    Mick, Rosemarie
    Roses, Robert E.
    Graves, Holly
    Niu, Huilin
    Sharma, Anupama
    Schueller, Jeanne E.
    Nisenbaum, Harvey
    Czerniecki, Brian J.
    Zhang, Paul J.
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (05) : 458 - 465
  • [28] A long term follow-up study of ductal carcinoma in situ in papilloma (DCIS-PAP).: Definition, prognostic significance and practical considerations
    de Mascarel, I
    MacGrogan, G
    Picot, V
    Mathoulin-Pélissier, S
    MODERN PATHOLOGY, 2002, 15 (01) : 32A - 32A
  • [29] A long term follow-up study of ductal carcinoma in situ in papilloma (DCIS-PAP).: Definition, prognostic significance and practical considerations
    de Mascarel, I
    MacGrogan, G
    Picot, V
    Mathoulin-Pélissier, S
    LABORATORY INVESTIGATION, 2002, 82 (01) : 32A - 32A
  • [30] Relationship between HER2 overexpression and long-term outcomes of early gastric cancer: a prospective observational study with a 6-year follow-up
    Li, Hui
    Li, Longsong
    Zhang, Nan
    Wang, Zixin
    Xu, Ning
    Linghu, Enqiang
    Chai, Ningli
    BMC GASTROENTEROLOGY, 2022, 22 (01)
12345